CN1315465C - Lonicera flower mango drip pill and its preparation method - Google Patents
Lonicera flower mango drip pill and its preparation method Download PDFInfo
- Publication number
- CN1315465C CN1315465C CNB2005100711108A CN200510071110A CN1315465C CN 1315465 C CN1315465 C CN 1315465C CN B2005100711108 A CNB2005100711108 A CN B2005100711108A CN 200510071110 A CN200510071110 A CN 200510071110A CN 1315465 C CN1315465 C CN 1315465C
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- mixed
- substrate
- extract
- drug extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a medicinal composition which has the functions of wind expelling, heat elimination, cough relief and phlegm dissipation, and is used for treating pharyngalgia, itching throat, tussis, upper respiratory tract infection, bronchitis, etc. The present invention aims to overcome the defects of the existing oral medicinal preparation for treating the diseases and provide an oral preparation-a honeysuckle flower mango drop pill which has the advantages of high biological utilization rate, rapid medicine release, rapidness for taking effect, high medicinal content, convenience for taking, low price, and no pollution in a production process. The present invention relates to a honeysuckle flower mango drop pill and is prepared from the extract of active ingredients of 7 kinds of traditional Chinese medicine as raw material and a medicinal carrier used as a base medium, wherein the 7 kinds of traditional Chinese medicine comprise honeysuckle flower, mango leaf, mongolian dandelion herb, platycodon root, sessile stemona root, tangerine peel, liquoric root, etc.
Description
Technical field
The present invention relates to a kind of wind and heat dispersing that has, the relieving cough and resolving phlegm effect, be used for pharyngalgia, itching of the throat, cough, upper respiratory tract infection, the pharmaceutical composition of treatment for diseases such as bronchitis is a kind of drug composition oral preparation that feedstock production forms with the extract that contains 7 flavor active ingredient of Chinese herbs such as Flos Lonicerae, Folium mangiferae, Herba Taraxaci, Radix Platycodonis, the Radix Stemonae, Pericarpium Citri Reticulatae, Radix Glycyrrhizae particularly.
Background technology
The Lonicera flower mango granule that is prepared from according to the preparation method that provides among the national drug standards WS-10890 (ZD-0890)-2002, it is a kind of wind and heat dispersing that has, the relieving cough and resolving phlegm effect, be used for pharyngalgia, itching of the throat, cough, upper respiratory tract infection, the oral granular formulation of treatment for diseases such as bronchitis is through clinical verification, determined curative effect is the common drug that clinical and family is used for the treatment of above-mentioned disease.Below be prescription and technology and the brief description that provides among the drug standard WS-10890 (ZD-0890)-2002:
Prescription: Flos Lonicerae 67g, Folium mangiferae 100g, Herba Taraxaci 200g, Radix Platycodonis 67g, Radix Stemonae 67g, Pericarpium Citri Reticulatae 100g, Radix Glycyrrhizae 67g, sucrose 933g
Method for making: above seven flavor medicine material decocts with water secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, filtrate is concentrated into the clear paste that relative density is 1.20 (80 ℃), adds ethanol and makes and contain alcohol amount to 63%, stirs evenly, left standstill 48 hours, and filtered, filtrate is concentrated into the clear paste that relative density is 1.16～1.25 (80 ℃), add sucrose and ethanol, stir evenly, make granule, drying, promptly.
Function cures mainly: wind and heat dispersing, relieving cough and resolving phlegm.Be used for pharyngalgia, itching of the throat, cough due to the affection due to external wind and heat, upper respiratory tract infection, acute bronchitis, the person that sees the above-mentioned symptom.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.The medicament contg of granule is also lower, takes inconvenience.
In addition, conventional peroral dosage form is as tablet, capsule, granule (electuary) etc., in preparation process because the technology of granulation is arranged, therefore can produce bigger dust pollution, can staff's health be worked the mischief to a certain extent, also can cause certain pollution simultaneously to environment.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
Purpose of the present invention, be to replenish existing be used for pharyngalgia, itching of the throat, cough, upper respiratory tract infection, the deficiency of the oral drug preparation of treatment for diseases such as bronchitis provides a kind of bioavailability height, and has a quick release, quick produce effects, medicament contg height, taking convenience, cheap, and free of contamination aborning oral formulations Lonicera flower mango drip pill.Lonicera flower mango drip pill involved in the present invention is a raw material with the extract that contains 7 flavor active ingredient of Chinese herbs such as Flos Lonicerae, Folium mangiferae, Herba Taraxaci, Radix Platycodonis, the Radix Stemonae, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, is prepared from the pharmaceutically suitable carrier as substrate.
Be prepared by the following technical solutions, can obtain Lonicera flower mango drip pill involved in the present invention:
[preparation method]
1. the preparation of drug extract: extracting honeysuckle 67g, Folium mangiferae 100g, Herba Taraxaci 200g, Radix Platycodonis 67g, Radix Stemonae 67g, Pericarpium Citri Reticulatae 100g, Radix Glycyrrhizae 67g, above seven flavor medicine material decocts with water secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction, filter, it is 1.20 clear paste that filtrate is concentrated into relative density, adds ethanol and makes and contain the alcohol amount to 63%, stir evenly, left standstill 48 hours, filter, it is 1.25～1.35 thick paste that filtrate is concentrated into relative density, or continue to make drying, be ground into dry powder, that is:
2. substrate: the mixture of one or more in pharmaceutically suitable carrier such as polyethylene glycols, sorbitol anhydride class, polyoxyethylene sorbitol acid anhydride class, polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, sweet pool gelatin, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. according to the given ratio of prescription, accurately take by weighing drug extract and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～90) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. when treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively and reaching desired state of temperature, to contain the fused solution of drug extract and substrate and/or emulsion and/or suspension places in the water dropper jar of drop pill machine, splash in the condensing agent, condensing agent can be any one in liquid paraffin, methyl-silicone oil, the vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.
[beneficial effect]
The Lonicera flower mango granule that is prepared from according to the preparation method that provides among the national drug standards WS-10890 (ZD-0890)-2002, it is a kind of wind and heat dispersing that has, the relieving cough and resolving phlegm effect, be used for pharyngalgia, itching of the throat, cough, upper respiratory tract infection, the oral granular formulation of treatment for diseases such as bronchitis is through clinical verification, determined curative effect is the common drug that clinical and family is used for the treatment of above-mentioned disease.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.The medicament contg of granule is also lower, takes inconvenience.
In addition, conventional peroral dosage form is as tablet, capsule, granule (electuary) etc., in preparation process because the technology of granulation is arranged, therefore can produce bigger dust pollution, can staff's health be worked the mischief to a certain extent, also can cause certain pollution simultaneously to environment.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Lonicera flower mango drip pill involved in the present invention is compared with the Lonicera flower mango granule has following beneficial effect:
1. Lonicera flower mango drip pill involved in the present invention; utilize surfactant to be substrate; with contain Flos Lonicerae; Folium mangiferae; Herba Taraxaci; Radix Platycodonis; the Radix Stemonae; Pericarpium Citri Reticulatae; the extract of 7 flavor Chinese medicine active pharmaceutical ingredients such as Radix Glycyrrhizae is made solid dispersion together; make medicine be molecule; colloid or microcrystalline state are scattered in the substrate; the total surface area of medicine increases; and substrate is hydrophilic; medicine had wetting action; can make medicine molten microgranule or the solution of loosing into rapidly; thereby make the dissolving of medicine and absorb quickening; thereby improved bioavailability, performance is efficient; quick-acting effects etc.
2. Lonicera flower mango drip pill involved in the present invention, contact promptly with saliva and to dissolve rapidly, and absorb by oral mucosa, not only rapid-action, and the influence of not taken food, promptly all can containing take after meal ante cibum, can not produce any residual harmful substance at gastric yet, thereby make that patient's medication is safer, also have medication convenience, characteristic of accurate simultaneously.
3. Lonicera flower mango drip pill involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
5. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind, and compares with oral liquid, and the dosage of drop pill is accurate, thereby makes the patient take metering control easily.
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of Lonicera flower mango drip pill of the present invention.
First group: the test of single-matrix
1. raw material: it is standby to make the extract dry powder that contains 7 flavor Chinese medicine active pharmaceutical ingredients such as Flos Lonicerae, Folium mangiferae, Herba Taraxaci, Radix Platycodonis, the Radix Stemonae, Pericarpium Citri Reticulatae, Radix Glycyrrhizae earlier according to [appendix];
2. substrate: Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the Lonicera flower mango drip pill of different size.
[result of the test]
Test 1: for observe drug extract and different substrates when 1: 1 the proportioning prepared Lonicera flower mango drip pill in qualitative difference, according to 1: 1 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 1.
Test 2: for observe drug extract and different substrates when 1: 3 the proportioning prepared Lonicera flower mango drip pill in qualitative difference, according to 1: 3 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 2.
Test 3: for observe drug extract and different substrates when 1: 9 the proportioning prepared Lonicera flower mango drip pill in qualitative difference, according to 1: 9 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as span 40, polyoxyethylene stearate 40 esters, poloxamer, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 3.
Second group: the test of mixed-matrix
1. raw material: it is standby to make the extract dry powder that contains 7 flavor Chinese medicine active pharmaceutical ingredients such as Flos Lonicerae, Folium mangiferae, Herba Taraxaci, Radix Platycodonis, the Radix Stemonae, Pericarpium Citri Reticulatae, Radix Glycyrrhizae earlier according to [appendix];
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the Lonicera flower mango drip pill of different size.
[result of the test]
Test 4: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 4.
Test 5: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 5.
Test 6: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 6.
Test 7: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 7.
Test 8: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 8.
Test 9: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 9.
Test 10: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 10.
Test 11: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 11.
Test 12: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Lonicera flower mango drip pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 12.
The group practices of table 1 drug extract and single-matrix
(drug extract: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 50.0 | 66 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 50.0 | 84 | ＜30 | ＞10 | + |
| Polyethylene Glycol 6000 | 50.0 | 84 | ＜30 | ＞10 | + |
| Polyethylene Glycol 10000 | 50.0 | 85 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 20000 | 50.0 | 85 | ＜30 | ＞10 | ++ |
| Span 40 | 50.0 | 63 | ＜30 | ＞10 | ++ |
| Polyoxyethylene stearate 40 esters | 50.0 | 78 | ＜30 | ＞10 | ++ |
| Poloxamer | 50.0 | 78 | ＜30 | ＞10 | ++ |
| Sodium lauryl sulphate | 50.0 | 73 | ＞30 | ＞10 | ++ |
| Stearic acid | 50.0 | 62 | ＞30 | ＞10 | ++ |
| Sodium stearate | 50.0 | 61 | ＞30 | ＞10 | ++ |
| Glycerin gelatine | 50.0 | 61 | ＞30 | ＞10 | + |
| Lac | 50.0 | 62 | ＞30 | ＞10 | + |
The group practices of table 2 drug extract and single-matrix
(drug extract: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 25.0 | 73 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 25.0 | 88 | ＜30 | ＜10 | ++ |
| Polyethylene Glycol 6000 | 25.0 | 89 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 25.0 | 91 | ＜30 | ＜10 | +++ |
| Span 40 | 25.0 | 76 | ＜30 | ＞10 | +++ |
| Polyoxyethylene stearate 40 esters | 25.0 | 90 | ＜30 | ＜10 | ++ |
| Poloxamer | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Sodium lauryl sulphate | 25.0 | 76 | ＜30 | ＞10 | ++ |
| Stearic acid | 25.0 | 76 | ＞30 | ＞10 | +++ |
| Sodium stearate | 25.0 | 72 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 25.0 | 73 | ＞30 | ＞10 | +++ |
| Lac | 25.0 | 73 | ＞30 | ＞10 | +++ |
The group practices of table 3 drug extract and single-matrix
(drug extract: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 10.0 | 81 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 10.0 | 90 | ＜30 | ＜10 | ++ |
| Polyethylene Glycol 6000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 10.0 | 93 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 10.0 | 93 | ＜30 | ＜10 | +++ |
| Span 40 | 10.0 | 74 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 10.0 | 91 | ＜30 | ＜10 | ++ |
| Poloxamer | 10.0 | 91 | ＜30 | ＜10 | +++ |
| Sodium lauryl sulphate | 10.0 | 76 | ＜30 | ＞10 | +++ |
| Stearic acid | 10.0 | 76 | ＞30 | ＞10 | +++ |
| Sodium stearate | 10.0 | 74 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 10.0 | 73 | ＞30 | ＞10 | +++ |
| Lac | 10.0 | 72 | ＞30 | ＞10 | +++ |
The group practices of table 4 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 50 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 50 | 84 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 50 | 82 | ＜30 | ＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 50 | 78 | ＜30 | ＞10 | + |
The group practices of table 5 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 25 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 25 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 25 | 88 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 25 | 84 | ＜30 | ＞10 | ++ |
The group practices of table 6 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 10 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 10 | 90 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 10 | 88 | ＜30 | ＞10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 10 | 83 | ＜30 | ＞10 | +++ |
The group practices of table 7 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 50 | 87 | ＜30 | ＜10 | ++ |
The group practices of table 8 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 25 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 25 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 25 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 25 | 88 | ＜30 | ＜10 | +++ |
The group practices of table 9 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 10 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 10 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 10 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 10 | 89 | ＜30 | ＜10 | +++ |
The group practices of table 10 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 50 | 93 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 50 | 93 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 50 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 50 | 89 | ＜30 | ＞10 | +++ |
The group practices of table 11 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 25 | 93 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 25 | 93 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 25 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 25 | 87 | ＜30 | ＜10 | +++ |
The group practices of table 12 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 10 | 89 | ＜30 | ＜10 | +++ |
1. can be seen by the result in the table: when the ratio of drug extract and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all undesirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of drug extract and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when this example of drug extract and substrate is 1: 9, the rounding rate, the ball method of double differences is different and index such as hardness improves not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly is out of shape, " ++ " expression distortion of firmly pressing, and " +++" expression is indeformable by it.
Claims (2)
1. a Lonicera flower mango drip pill is a raw material with Flos Lonicerae, Folium mangiferae, Herba Taraxaci, Radix Platycodonis, the Radix Stemonae, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, is prepared from the pharmaceutically suitable carrier as substrate, it is characterized in that:
(1) extracting honeysuckle 67g, Folium mangiferae 100g, Herba Taraxaci 200g, Radix Platycodonis 678, Radix Stemonae 67g, Pericarpium Citri Reticulatae 100g, Radix Glycyrrhizae 67g, more than seven the flavor, decoct with water secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, it is 1.20 clear paste that filtrate is concentrated into relative density, add ethanol and make and contain alcohol amount, stir evenly, left standstill 48 hours to 63%, filter, it is 1.25～1.35 thick paste that filtrate is concentrated into relative density, or continues to make drying, is ground into dry powder, promptly get the extract that contains pharmaceutically active ingredient in above-mentioned 7 kinds, standby;
(2) described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or carboxymethyl starch sodium; By weight, the mixed proportion of polyoxyethylene stearate 40 esters or carboxymethyl starch sodium and Polyethylene Glycol is 1: 1～1: 10, and the ratio of described extract and described substrate is 1: 3;
(3) according to aforementioned proportion, accurately take by weighing described extract and substrate, be placed in the heating container heating while stirring, until obtaining containing the extract of pharmaceutically active ingredient in above-mentioned 7 kinds and the fused solution of substrate, or emulsion, or suspension, standby;
(4) temperature control system of adjustment drop pill machine makes the water dropper temperature heating of drop pill machine and remains on 50 ℃～90 ℃, and the temperature cooling of condensing agent also remains on 40 ℃～-5 ℃;
When (5) temperature for the treatment of dropping-pill machine head and condensing agent reaches described state of temperature respectively, will contain the fused solution of described extract and substrate, or emulsion, or suspension, place in the water dropper jar of drop pill machine, splash in the condensing agent and shrink molding promptly;
2. Lonicera flower mango drip pill according to claim 1 is characterized in that: described condensing agent be methyl-silicone oil or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100711108A CN1315465C (en) | 2005-05-20 | 2005-05-20 | Lonicera flower mango drip pill and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100711108A CN1315465C (en) | 2005-05-20 | 2005-05-20 | Lonicera flower mango drip pill and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686477A CN1686477A (en) | 2005-10-26 |
| CN1315465C true CN1315465C (en) | 2007-05-16 |
Family
ID=35304519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100711108A Expired - Fee Related CN1315465C (en) | 2005-05-20 | 2005-05-20 | Lonicera flower mango drip pill and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1315465C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352912A (en) * | 2014-11-26 | 2015-02-18 | 黑龙江省智诚医药科技有限公司 | Honeysuckle and mango dispersible tablets and preparation method thereof |
| CN115227786A (en) * | 2022-08-31 | 2022-10-25 | 神木市神怡农业科技发展有限公司 | A Chinese medicinal composition comprising herba Sonchi Oleracei as principal drug for clearing away heat and toxic materials, and its preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1544042A (en) * | 2003-11-12 | 2004-11-10 | 北京正大绿洲医药科技有限公司 | Liuwei Dihuang dripping pills and its preparation |
-
2005
- 2005-05-20 CN CNB2005100711108A patent/CN1315465C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1544042A (en) * | 2003-11-12 | 2004-11-10 | 北京正大绿洲医药科技有限公司 | Liuwei Dihuang dripping pills and its preparation |
Non-Patent Citations (1)
| Title |
|---|
| 国家中成药标准汇编(中成药地方标准上升国家标准部分) 国家药典委员会，108 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686477A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100542516C (en) | Dropping pill of folium ilicis hainanensis and preparation method thereof | |
| CN1322855C (en) | Oral drop pill in use for clearing away heat and toxic material and preparation method | |
| CN100382785C (en) | Cough suppressing phlegm transforming drip pill and its preparation method | |
| CN100358501C (en) | Tranquilizing wild jujube seed dripping pill and its preparing method | |
| CN100382786C (en) | Bastard feverfew throat clearing drip pill and its preparation method | |
| CN1315471C (en) | Basis-reinforcing eyesight-improving dropping pill for treating eye disease and its preparing method | |
| CN1315465C (en) | Lonicera flower mango drip pill and its preparation method | |
| CN100367936C (en) | Oral drop pill in use for clearing sway heat and toxic material, relieving inflammation and dysentery, and preparation method | |
| CN100364513C (en) | 'Gansu' dripping pills for treating hepatitis and its preparation method | |
| CN100348215C (en) | Kaihoujian drip pill for treating throat disease and its preparation method | |
| CN100375608C (en) | Tortoise-astragalus root-ginseng dripping pill and its preparing method | |
| CN1322857C (en) | Xiaoke drip pill used for suppressing cough and transforming phlegm and its preparation method | |
| CN100358504C (en) | Gastrodia brain arousing drip pill for nourishing liver and kidney and its preparation method | |
| CN100348177C (en) | Two kinds of oral drip pills for treating tracheitis and its preparation method | |
| CN1315461C (en) | Jaundice capillaris drip pill and its preparation method | |
| CN1315469C (en) | Golden gallbladder-normalizing dropping pill for relaxing-liver and normalizing gallbladder, and its preparing method | |
| CN100367937C (en) | Throat dripping pill for clearing away heat and toxic material and its preparing method | |
| CN1315462C (en) | Throat clearing drip pill and its preparation method | |
| CN100427070C (en) | Dripping pills for treating all kinds of rhinitis and its preparation method | |
| CN100348175C (en) | Bistort drop pill and preparation method | |
| CN100367935C (en) | Oral drop pills in use for treating diseases of bacterial infection and preparation method | |
| CN100358531C (en) | Glycyrrhizin drop pills and preparation method thereof | |
| CN100364506C (en) | Drop pills preparation in use for treating bronchitis and preparation method | |
| CN1322854C (en) | Cold drop pills of mulberry and ginger in use for eliminating draft, clearing away heat, and preparing method | |
| CN100502903C (en) | Anshenning dripping pill for treating neurosism and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070516 Termination date: 20100520 |